Skip links

ANDEMBRY® (garadacimab-gxii)

Full Name ANDEMBRY® (garadacimab-gxii)
Drug garadacimab-gxii
Manufacturer CSL Behring
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website andembryhcp.com